Sarepta Therapeutics Management
Management criteria checks 2/4
Sarepta Therapeutics' CEO is Doug Ingram, appointed in Jun 2017, has a tenure of 9.08 years. total yearly compensation is $7.84M, comprised of 14.9% salary and 85.1% bonuses, including company stock and options. directly owns 0.37% of the company’s shares, worth $7.72M. The average tenure of the management team and the board of directors is 1 years and 10.1 years respectively.
Key information
Doug Ingram
Chief executive officer
US$7.8m
Total compensation
| CEO salary percentage | 14.94% |
| CEO tenure | 9.1yrs |
| CEO ownership | 0.4% |
| Management average tenure | 1yr |
| Board average tenure | 10.1yrs |
Recent management updates
Recent updates
Narrative Update • Jun 23
SRPT: Thin siRNA Data And Regulatory Shifts Will Pressure Overvalued Shares
Sarepta Therapeutics’ analyst price target has been reduced by $1 to $19. Analysts cite a slightly higher discount rate, a marginally weaker revenue growth outlook and a small trim to projected profit margins, partly offset by updated P/E assumptions.Analysis Article • Jun 21
Sarepta Therapeutics (SRPT) Stock Could Be 19% Undervalued As Elevidys Outlook Steadies
Recent commentary around Sarepta Therapeutics (SRPT) focuses on Elevidys, its gene therapy for Duchenne muscular dystrophy, with expectations of near term stabilization and renewed attention on the company’s siRNA pipeline and the evolving FDA stance. See our latest analysis for Sarepta Therapeutics. The recent focus on Elevidys and Sarepta Therapeutics’ siRNA programs comes after a mixed share price record, with a 14.5% 7 day share price return and year to date share price performance down...Seeking Alpha • Jun 18
Sarepta: Caution Still Warranted Despite FDA's Gene Therapy-Friendly Stance
Summary Sarepta Therapeutics, Inc. faces a challenging outlook, with 2025 marked by safety setbacks, missed endpoints, and a sharp share price decline. SRPT's 2026 guidance projects $1.2–$1.4bn in product revenues but relies heavily on regulatory outcomes for Elevidys and exon-skipping therapies. Recent FDA signals suggest a more gene therapy-friendly stance, potentially benefiting SRPT's Elevidys and upcoming siRNA programs. I maintain a hold rating on SRPT stock, leaning bullish if pivotal data and regulatory reviews favor Elevidys' broader use and full approvals for key assets. Read the full article on Seeking AlphaNarrative Update • Jun 06
SRPT: Thin siRNA Data And Regulatory Risks Will Pressure Overvalued Shares
Analysts have trimmed their average price target on Sarepta Therapeutics by $1 to $19, reflecting updated views on fair value, a slightly higher discount rate, and revised expectations for revenue growth, margins, and future P/E multiples. Analyst Commentary Recent research on Sarepta Therapeutics shows a split view, with some firms lifting price targets while others turning more cautious.
Narrative Update • May 23
SRPT: 2026 Guidance And siRNA Data Readouts Will Drive Upside Potential
Analysts trimmed Sarepta Therapeutics' average price target by $1 to $19, reflecting updated models that factor in revised 2026 guidance, a higher assumed discount rate, lower projected profit margins, and a higher future P/E multiple. Analyst Commentary Bullish analysts remain divided on Sarepta, but several recent research updates still point to constructive sentiment around execution on guidance, product launches, and the pipeline.Analysis Article • May 14
Sarepta Therapeutics (NASDAQ:SRPT) Is Posting Solid Earnings, But It Is Not All Good News
Investors appear disappointed with Sarepta Therapeutics, Inc.'s ( NASDAQ:SRPT ) recent earnings, despite the decent...Narrative Update • May 07
SRPT: 2026 Reset Year Guidance Will Pressure Overvalued Shares
Analysts have lowered their average price target on Sarepta Therapeutics by about $64. The change is tied to updated 2026 guidance, reduced revenue expectations for Elevidys and PMO products, and a lower future P/E assumption, despite generally mixed views on the siRNA and DM1 programs.Narrative Update • Apr 22
SRPT: 2026 Guidance And siRNA Pipeline Readouts Will Shape Upside Potential
Sarepta Therapeutics' updated analyst price target has shifted modestly, reflecting a lower fair value estimate of $37.42 and a reduced future P/E assumption as analysts weigh mixed siRNA data, updated 2026 revenue guidance, and varying views on Elevidys and the PMO franchise. Analyst Commentary Recent Street research on Sarepta shows a wide range of views, but several bullish analysts are leaning into updated company guidance and new clinical datapoints when revisiting their models.
Narrative Update • Apr 07
SRPT: Future Returns Will Depend On 2026 Reset And Mixed Pipeline Signals
Analysts have lifted the blended price target for Sarepta Therapeutics by about $1 to $2, reflecting recent target revisions that balance cautious views on Elevidys revenue guidance and siRNA data quality with more constructive perspectives on early DM1 results and updated 2026 sales and expense models. Analyst Commentary Recent research paints a mixed picture for Sarepta, with analysts updating models around Elevidys, siRNA programs, and early DM1 data.Narrative Update • Mar 23
SRPT: Future Upside Will Hinge On 2026 Gene Therapy Launch Reset
Analysts made a modest upward adjustment to Sarepta Therapeutics' fair value estimate, reflecting updated models around Elevidys launch pacing, 2026 revenue guidance, and revised expectations for profitability and future P/E multiples following recent Q4 results and regulatory commentary. Analyst Commentary Street research on Sarepta around the Q4 update and 2026 guidance reflects a wide range of views on execution risk, Elevidys launch pacing, and the durability of the exon-skipping and gene therapy portfolio.Narrative Update • Mar 09
SRPT: Future Upside Will Depend On 2026 Gene Therapy Execution
The analyst price target for Sarepta Therapeutics has moved slightly lower to align with revised 2026 revenue expectations and product launch assumptions, with recent Street targets stepping down in a range from about $45 to $8 as analysts recalibrate Elevidys and other franchise contributions. Analyst Commentary Street views on Sarepta are split, with several firms cutting price targets after management issued 2026 revenue guidance that appears lower than earlier assumptions, while others still see room for execution on the Elevidys and exon-skipping franchises to support value over time.Narrative Update • Feb 22
SRPT: Future Risk Reward Will Hinge On Elevidys Execution And Patent Overhang
The analyst price target for Sarepta Therapeutics has been raised by about $0.80. Analysts point to slightly higher fair value estimates, a modestly firmer long term profit margin outlook and updated P/E assumptions, even as they factor in a slightly higher discount rate and restrained revenue expectations.Narrative Update • Feb 08
SRPT: Upcoming 2026 Clinical And Regulatory Milestones Will Drive Future Upside
Analysts have edged their price targets on Sarepta Therapeutics higher, with a modest fair value increase of about $0.20 per share. Slightly stronger long run profit expectations more than offset softer modeled revenue growth and a small trim to the assumed future P/E multiple.Narrative Update • Jan 25
SRPT: Gene Therapy Catalysts And Access Updates Will Drive Future Upside
Analysts nudged their price target on Sarepta Therapeutics slightly higher, lifting fair value by about US$0.33 to US$39.90 as they factor in updated expectations for Elevidys sales, profitability, and a modestly higher discount rate. Analyst Commentary Recent research on Sarepta highlights a split view on Elevidys, with some pointing to softer near term sales and others focusing on what they see as growing adoption and a broader pipeline story.Narrative Update • Jan 10
SRPT: Elevidys Adoption And Pipeline Progress Will Drive Future Upside
Analysts have reset their fair value estimate for Sarepta Therapeutics from US$55.90 to US$39.56. This reflects updated assumptions for revenue growth, profit margins, and a higher future P/E multiple following recent research that highlights both improved confidence in Elevidys adoption and ongoing caution from some covering firms.Narrative Update • Dec 25
SRPT: Future Risk Reward Will Hinge On Evolving Safety And Coverage Decisions
The analyst price target for Sarepta Therapeutics has been raised slightly, by about $0.20 per share. Analysts attribute this to stronger than expected Elevidys adoption, supportive payer coverage, and a more favorable risk and reward profile, despite unchanged long-term growth and margin assumptions.Narrative Update • Dec 11
SRPT: Safety Reviews And Payer Decisions Will Shape Future Risk Reward Balance
Sarepta Therapeutics' fair value estimate has been raised modestly to approximately $20.43 from $19.91, as analysts factor in stronger than expected Elevidys adoption and a more favorable risk or reward profile, despite only incremental improvements in revenue growth and discount rate assumptions. Analyst Commentary Street research on Sarepta has turned more constructive at the margin, with multiple models recalibrated around stronger Elevidys uptake and a clearer path to reimbursement.Analysis Article • Dec 04
There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues Despite A 35% Share Price Rise
Sarepta Therapeutics, Inc. ( NASDAQ:SRPT ) shareholders would be excited to see that the share price has had a great...Narrative Update • Nov 27
SRPT: Ongoing Regulatory Reviews And Safety Updates Will Shape Near-Term Prospects
The analyst price target for Sarepta Therapeutics has been modestly reduced from approximately $21.55 to $19.91. Analysts express mixed expectations based on recent shifts in profit margin projections and ongoing evaluations of Elevidys adoption and safety dynamics.Narrative Update • Nov 05
SRPT: Upcoming Clinical Data Will Drive Renewed Momentum In Gene Therapy Efforts
Sarepta Therapeutics' analyst price target has been revised downward from approximately $22.88 to $21.55 per share. Analysts cite ongoing concerns over Elevidys uptake, modest improvements to revenue outlook, and persistent profit margin pressures.Analysis Article • Oct 18
Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Shares Bounce 32% But Its Business Still Trails The Industry
Despite an already strong run, Sarepta Therapeutics, Inc. ( NASDAQ:SRPT ) shares have been powering on, with a gain of...Narrative Update • Sep 26
Upcoming ELEVIDYS And Gene Therapy Updates Will Restore Patient Trust
Sarepta Therapeutics’ consensus price target has been lowered from $23.96 to $22.88, primarily due to ongoing Elevidys safety concerns, regulatory uncertainty, and negative sentiment over recent management decisions, outweighing the short-term relief from improved liquidity and regulatory clarity. Analyst Commentary Elevidys safety concerns, including recent patient deaths and new serious adverse event reports, have sustained regulatory uncertainty and contributed to ongoing negative sentiment and price target reductions by Bearish analysts.Narrative Update • Sep 04
Upcoming ELEVIDYS And Gene Therapy Updates Will Restore Patient Trust
Sarepta Therapeutics’ price target remains under pressure due to persistent safety concerns and regulatory uncertainty surrounding Elevidys, limited market scope after clinical setbacks and halted non-ambulatory development, and skepticism about long-term cash generation, resulting in a maintained consensus analyst price target of $23.84. Analyst Commentary Continued safety concerns surrounding Elevidys, particularly following patient deaths and serious adverse events (notably acute liver failure in non-ambulatory patients and new adverse event reports), have caused repeated reductions in revenue forecasts and increased uncertainty about regulatory approval and commercial uptake.Analysis Article • May 29
We Think The Compensation For Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Looks About Right
Key Insights Sarepta Therapeutics to hold its Annual General Meeting on 5th of June CEO Doug Ingram's total...Analysis Article • May 08
The Consensus EPS Estimates For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Just Fell A Lot
Today is shaping up negative for Sarepta Therapeutics, Inc. ( NASDAQ:SRPT ) shareholders, with the analysts delivering...Analysis Article • Apr 20
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Not Doing Enough For Some Investors As Its Shares Slump 27%
To the annoyance of some shareholders, Sarepta Therapeutics, Inc. ( NASDAQ:SRPT ) shares are down a considerable 27% in...Seeking Alpha • Mar 18
Sarepta: Disclosure Of An Elevidys Patient's Death Creates Market Uncertainty
Summary Sarepta Therapeutics stock dropped over 20% after a patient treated with Elevidys for DMD died from acute liver failure, raising safety concerns. Despite the incident, Sarepta maintains that the benefit-risk profile of Elevidys remains positive, and over 800 patients have been treated without such severe adverse events. Sarepta's strong financial performance and growth prospects for Elevidys and other therapies may be clouded somewhat by potential regulatory and market reactions to the safety event. Given the uncertainty and need for further data, I am revising my rating on SRPT stock from "Buy" to "Hold" to exercise caution. Read the full article on Seeking AlphaCEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$65m |
| Dec 31 2025 | US$8m | US$1m | -US$713m |
| Sep 30 2025 | n/a | n/a | -US$272m |
| Jun 30 2025 | n/a | n/a | -US$58m |
| Mar 31 2025 | n/a | n/a | -US$248m |
| Dec 31 2024 | US$2m | US$847k | US$235m |
| Sep 30 2024 | n/a | n/a | US$122m |
| Jun 30 2024 | n/a | n/a | US$47m |
| Mar 31 2024 | n/a | n/a | US$17m |
| Dec 31 2023 | US$2m | US$800k | -US$536m |
| Sep 30 2023 | n/a | n/a | -US$691m |
| Jun 30 2023 | n/a | n/a | -US$908m |
| Mar 31 2023 | n/a | n/a | -US$1b |
| Dec 31 2022 | US$125m | US$740k | -US$703m |
| Sep 30 2022 | n/a | n/a | -US$716m |
| Jun 30 2022 | n/a | n/a | -US$507m |
| Mar 31 2022 | n/a | n/a | -US$357m |
| Dec 31 2021 | US$2m | US$730k | -US$419m |
| Sep 30 2021 | n/a | n/a | -US$486m |
| Jun 30 2021 | n/a | n/a | -US$634m |
| Mar 31 2021 | n/a | n/a | -US$704m |
| Dec 31 2020 | US$1m | US$669k | -US$554m |
| Sep 30 2020 | n/a | n/a | -US$601m |
| Jun 30 2020 | n/a | n/a | -US$530m |
| Mar 31 2020 | n/a | n/a | -US$656m |
| Dec 31 2019 | US$1m | US$650k | -US$715m |
Compensation vs Market: Doug's total compensation ($USD7.84M) is above average for companies of similar size in the US market ($USD5.13M).
Compensation vs Earnings: Doug's compensation has been consistent with company performance over the past year.
CEO
Doug Ingram (63 yo)
9.1yrs
Tenure
US$7,840,666
Compensation
Mr. Douglas S. Ingram, J.D., Esq., also known as Doug, served as Independent Director of Arrowhead Pharmaceuticals, Inc. since February 06, 2025 until March 20, 2026. He has been Chief Executive Officer Sa...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 9.1yrs | US$7.84m | 0.37% $ 7.7m | |
| President & COO | 1yr | US$4.44m | 0.030% $ 617.8k | |
| Executive VP & CFO | 1yr | US$3.21m | 0.011% $ 227.9k | |
| Executive VP | 1.7yrs | US$4.23m | no data | |
| President of Research & Development and Technical Operations | 1yr | US$4.46m | 0.052% $ 1.1m | |
| Chief Scientific Officer | 1yr | no data | no data | |
| Director of Finance | no data | no data | no data | |
| Executive VP & Chief People Officer | 4.8yrs | no data | no data | |
| Executive VP and Chief of Global Policy & Advocacy Officer | 6.8yrs | no data | no data | |
| Executive VP & Chief Commercial Officer | 1yr | no data | no data | |
| Executive VP & Chief Medical Officer | less than a year | no data | no data | |
| Controller & VP | 9.3yrs | US$911.89k | no data |
1.0yrs
Average Tenure
54yo
Average Age
Experienced Management: SRPT's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 9.1yrs | US$7.84m | 0.37% $ 7.7m | |
| Independent Chairwoman | 17.3yrs | US$603.92k | 0.20% $ 4.1m | |
| Chairman of Corporate Strategy Board & Independent Non-Employee Director | 16.1yrs | US$562.47k | 0.024% $ 499.1k | |
| Independent Director | 11.1yrs | US$577.28k | 3.05% $ 63.7m | |
| Member of Strategic & Scientific Advisory Board | 10.9yrs | no data | no data | |
| Independent Director | 1.8yrs | US$558.15k | 0.0032% $ 65.8k | |
| Member of Scientific Advisory Board | 6.7yrs | no data | no data | |
| Member of Strategic & Scientific Advisory Board | 10.9yrs | no data | no data | |
| Independent Non-Employee Director | 11.1yrs | US$554.47k | 0.030% $ 624.1k | |
| Member of Strategic & Scientific Advisory Board | 9.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 6.6yrs | no data | no data | |
| Member of Strategic & Scientific Advisory Board | 9.3yrs | no data | no data |
10.1yrs
Average Tenure
70yo
Average Age
Experienced Board: SRPT's board of directors are seasoned and experienced ( 10.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/08 21:56 |
| End of Day Share Price | 2026/07/08 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sarepta Therapeutics, Inc. is covered by 49 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Huidong Wang | Barclays |
| Eliana Merle | Barclays |